* Consumer Health CEO outlines region prospects at FT OTC conference
* New product launch across Latin America planned for 2016
* Consumerization approach and 3x3 strategy sustain Latin America’s growth
* Demand in Latin America region fuels double-digit sales growth in Q2 2015

DARMSTADT, Germany--(Antara/BUSINESS WIRE)-- Merck, a leading company for innovative, top-quality high-tech products in healthcare, life science and performance materials, expects the Latin America region to keep driving growth at its Consumer Health business, as demand for consumer goods in the region is constantly rising.

“Along with a growing consumer demand, Latin America sees a rise in the need for healthcare products and a trend towards consumer goods making daily life more convenient,” said Uta Kemmerich-Keil, CEO and President of Merck’s Consumer Health business, at the Financial Times Latin America Healthcare & Life Sciences Summit, held on 29 September 2015 in Miami, USA. “Our business is well positioned to anticipating the region’s rapidly changing demographics and responding to consumers’ healthcare needs.”

She detailed the business answers to emerging consumer trends such as increased investments into digital communication, and to the consolidation in the wholesale and pharmacy sector. Also, she outlined the business propositions to meet the needs of the local emerging middle classes, for example the consumerization of the Neurobion and Floratil brands as well as the geographic expansion of the Bion brand into Brazil. As a solid signal of Merck’s Consumer Health business commitment to the region, Kemmerich-Keil pre-announced the launch of a new innovative product across almost the entire Latin American region in 2016.

Latin America playing growth engine role

As the successful implementation of the 3x3 strategy in the region remains the focus – aiming at a minimum of 3% market share and at least 3 leading brands per market – Latin America has been showing the best performance for Consumer Health globally. The region is expected to see the majority of the business global strategic initiatives by the end of the decade. Consumer Health is present in the three biggest categories in the region: a) Vitamins, Minerals and Supplements; b) Cough and Cold; c) Allergy and Analgesics; all categories experiencing strong market growth of around 5%.

Latin America played a key role in the consumerization of Neurobion and Floratil from Merck Serono, the former most contributing to absolute growth in the region. In Brazil, the Floratil consumerization approach drove a 34% net sales growth in 2014 versus 2013 and the franchise is expected to be the second fastest growing in the Latin American portfolio by the end of the decade. Bion is expected to become the fastest growing brand in the region, after the successful launch of Bion3 in 2014 in Brazil. In Chile, thanks to a consumer approach with focus on digital already initiated in 2010, Bion3 has become the 2nd biggest OTC brand and the best-selling multivitamin with a market share of ~60%.

Q2 2015 organic sales growth

In the second quarter of 2015, Consumer Health reported net sales of € 227.6 million, indicating a strong 16% organic growth versus the year-earlier period. Consumer Health continues to be the fastest growing business at Merck. All global strategic brands outperformed versus last year with Neurobion, Dolo-Neurobion and Femibion being key contributors. Key geographies with strong growth momentum were Chile and Mexico for Latin America, as well as Indonesia and the Philippines for Asia Pacific.

# # #

About Merck’s Consumer Health Business

Brands of the Consumer Health business, such as Dolo-Neurobion®, Neurobion®, Bion®, Seven Seas®, Nasivin®, and Femibion® are innovative leaders in key markets, backed by science and trusted by consumers worldwide. The Consumer Health business is with over 2,700 employees globally active in over 40 markets. Since 2014, the portfolio comprises of brands with annual total sales of about $ 1 billion. Consumer Health is a business of the Healthcare business sector within the Merck Group with global headquarters in Darmstadt, Germany. For more information please go to www.merck-consumer-health.com.

All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

Merck is a leading company for innovative, top-quality high-tech products in healthcare, life science and performance materials. The company has six businesses – Merck Serono, Consumer Health, Allergopharma, Biosimilars, Merck Millipore and Performance Materials – and generated sales of around € 11.3 billion in 2014. Around 39,000 employees work for Merck in 66 countries to improve the quality of life for patients, to further the success of customers, and to help meet global challenges. Merck is the world’s oldest pharmaceutical and chemical company – since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70% interest, the founding family remains the majority owner of the company to this day. Merck, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are Canada and the United States, where the company operates as EMD Serono, EMD Millipore and EMD Performance Materials.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150928005589/en/


Merck Consumer Health
Dr. Lars Atorf
+49 6151 856-3114

Source: Merck

Reporter: PR Wire
Editor: PR Wire
Copyright © ANTARA 2015